<p>The US Food and Drug Administration declined Humanigen Inc's request for emergency use authorization (EUA) of its lenzilumab drug to treat newly hospitalized Covid-19 patients, the company said on Thursday.</p>.<p>"In its letter, FDA stated that it was unable to conclude that the known and potential benefits of lenzilumab outweigh the known and potential risks of its use as a treatment for Covid-19," the company said in a statement.</p>.<p>Humanigen expects an ongoing study to provide additional safety and efficacy data to support its new EUA request.</p>.<p>The company filed its application with the FDA for emergency use of the drug in May, citing late-stage trial data.</p>.<p>Humanigen also started the process of UK authorization for the drug in June through a rolling review submission.</p>.<p><strong>Check out DH's latest video:</strong></p>
<p>The US Food and Drug Administration declined Humanigen Inc's request for emergency use authorization (EUA) of its lenzilumab drug to treat newly hospitalized Covid-19 patients, the company said on Thursday.</p>.<p>"In its letter, FDA stated that it was unable to conclude that the known and potential benefits of lenzilumab outweigh the known and potential risks of its use as a treatment for Covid-19," the company said in a statement.</p>.<p>Humanigen expects an ongoing study to provide additional safety and efficacy data to support its new EUA request.</p>.<p>The company filed its application with the FDA for emergency use of the drug in May, citing late-stage trial data.</p>.<p>Humanigen also started the process of UK authorization for the drug in June through a rolling review submission.</p>.<p><strong>Check out DH's latest video:</strong></p>